MilliporeSigma

Feasibility of glucagon eyedrops for clinical use in hypoglycemia.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics (1995-01-01)
S X Liu, G C Chiou
ABSTRACT

Although sufficient amount of glucagon can be taken up into systemic circulation through ocular route, the concentration of eyedrops needed at 7.5% would be too high and the price of the doses would be too expensive to be desirable. Attempts have been made to reduce the doses of glucagon needed for systemic delivery through ocular route by adding absorption enhancers such as 0.5% BL-9 or 0.5% Brij-78. With these absorption enhancers, the effective concentrations of glucagon eyedrops can be lowered to 0.05% in rabbit eyes and could be lowered to 1.25% in human eyes which would be reasonable to be used in the clinics.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Brij® S 100, average Mn ~4,670
Sigma-Aldrich
Brij® S20
Sigma-Aldrich
SP Brij® S2 MBAL, main component: diethylene glycol octadecyl ether
Sigma-Aldrich
Brij® S10, average Mn ~711
Sigma-Aldrich
ECO Brij® S100, average Mn ~4,670
Sigma-Aldrich
ECO Brij® S20
Sigma-Aldrich
ECO Brij® S10, average Mn ~711